Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-07-05 Capital/Financing Update
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
4.Bone Therapeutics_Rapport Spécial du Conseil d_administration_7_180 7_191 et 7_193_Annex incl.PDF
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION ETABLI CONFORMEMENT AUX ARTICLES 7:180, 7:191 ET 7:193 DU CODE DES SOCIETES ET DES ASSOCIATIONS" (Special Report of the Board of Directors established in accordance with Articles 7:180, 7:191 and 7:193 of the Companies and Associations Code). This report details the justification for proposing the issuance of subscription rights (Droits de Souscription) related to a financing agreement with the European Investment Bank (BEI) and the conversion of convertible bonds. This type of detailed corporate action proposal, often required by specific national corporate law articles (here, Belgian law), falls under the category of Capital/Financing Update (CAP) as it directly concerns capital structure changes and fundraising activities. It is a comprehensive report detailing the terms of the proposed capital change, not just a brief announcement.
2021-07-05 French
7.Bone Therapeutics_EIB Finance Contract_fully executed.PDF
Capital/Financing Update Classification · 98% confidence The document text provided is a highly structured legal/financial agreement, specifically titled "Finance Contract" between "European Investment Bank" and "BONE THERAPEUTICS SA", dated June 30, 2021. It contains articles (ARTICLES) detailing terms like 'AMOUNT OF CREDIT', 'DISBURSEMENT PROCEDURE', 'CANCELLATION', and 'FEES'. This structure is characteristic of a formal financing agreement or a specific regulatory filing related to debt/capital structure, rather than a standard periodic report (like 10-K, IR, ER) or a shareholder communication (like DEF 14A, AGM-R). Reviewing the definitions: - 10-K/IR: These are comprehensive financial reports; this document is a contract. - ER/MRQ: These are earnings/results announcements; this is a contract. - DIV/NAV: Related to dividends or fund valuation; not applicable. - The document clearly outlines financing terms and credit amounts, making it highly relevant to capital structure changes or financing activities. Therefore, the most appropriate category is Capital/Financing Update (CAP), as it details the terms of a finance contract/credit facility. Confidence is high because the content explicitly deals with 'Finance Contract', 'AMOUNT OF CREDIT', and 'DISBURSEMENT PROCEDURE'.
2021-07-05 English
5.Bone Therapeutics_Rapport_spécial_art_7_228_continuité_signé FINAL.pdf
AGM Information Classification · 98% confidence The document is explicitly titled "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION Á L'ASSEMBLÉE GÉNÉRALE ÉTABLI CONFORMEMENT Á L'ARTICLE 7:228 DU CODE DES SOCIÉTÉS ET DES ASSOCIATIONS" (Special Report of the Board of Directors to the General Meeting established in accordance with Article 7:228 of the Companies and Associations Code). This report addresses the company's net assets falling below half of its share capital, requiring the Board to report to the General Meeting on measures to ensure continuity or propose dissolution. This content is directly related to the proceedings and materials presented at the Annual General Meeting (AGM) concerning the company's legal status and continuity plan, which aligns best with the 'AGM Information' category, as it is a formal report prepared for that specific meeting.
2021-07-05 French
8.Bone Therapeutics_Warrant Agreement_fully executed.PDF
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "SUBSCRIPTION AGREEMENT FOR WARRANTS IN THE CAPITAL OF BONE THERAPEUTICS SA" and details the terms under which the European Investment Bank (Subscriber) agrees to subscribe for warrants issued by Bone Therapeutics SA (Issuer). This agreement concerns the issuance of securities (warrants) and the associated financing/capital structure change. This aligns best with the 'Capital/Financing Update' category, which covers company fundraising, financing activities, or capital structure changes. It is a definitive legal agreement, not a general announcement (RPA/RNS) or a standard periodic report (10-K/IR).
2021-07-05 English
6.Bone Therapeutics_Auditor Report_Art7.180-7.191 et 7.193_SignedByDeloitte.pdf
Capital/Financing Update Classification · 98% confidence The document is titled 'Rapport du commissaire dans le cadre de l'émission de droit de souscription et de la suppression du droit de préférence...' and explicitly references articles 7:180, 7:191, and 7:193 of the Belgian Code des sociétés et des associations. It contains the report from the statutory auditor (DELOITTE) evaluating the special report from the board regarding the issuance of subscription rights (warrants) and the cancellation of pre-emptive rights related to financing from the European Investment Bank (BEI) and conversion of convertible bonds. This structure—a formal report by an auditor concerning a proposed capital operation (issuance of rights/warrants) requiring shareholder approval and justification under corporate law—strongly indicates a filing related to capital structure changes or financing activities. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the mechanics and justification for issuing new instruments tied to a loan agreement, rather than being a general annual report (10-K), an interim report (IR), or a simple announcement of a report (RPA).
2021-07-05 French
1EN.Bone Therapeutics_EGM-20210805_Convening notice.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "INVITATION TO THE EXTRAORDINARY SHAREHOLDERS' MEETING HELD ON 5 AUGUST 2021". It details the agenda, proposed resolutions, and procedures for a general meeting of shareholders. This content directly relates to the formal gathering of shareholders to vote on corporate matters, which aligns perfectly with the definition of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) material. The code for AGM materials is AGM-R.
2021-07-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.